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http:WHAT THIS PAPER ADDS
The value of adjunctive hyperbaric oxygen therapy (HBOT) in the treatment of diabetic foot ulcers has been
questioned in meta-analyses of randomized clinical trials (RCTs). Yet, because of signiﬁcant clinical heterogeneity
between the trials, pooling of data is considered to be inappropriate. Some evidence was found for HBOT
improving rates of complete wound healing in patients with a diabetic foot ulcer and concomitant ischaemia, as
opposed to non-ischaemic ulcers. A consistent effect on amputation rates was not found. Additional trials are
necessary to justify routine use of HBOT in patients with diabetic ulcers.Objective: A systematic review of randomized clinical trials (RCTs) to assess the additional value of hyperbaric
oxygen therapy (HBOT) in promoting the healing of diabetic foot ulcers and preventing amputations was
performed.
Methods: MEDLINE, Embase, and the Cochrane Library were searched to identify RCTs in patients with diabetic
foot ulcers published up to August 2013. Eligible studies reported the effectiveness of adjunctive HBOT with
regard to wound healing, amputations, and additional interventions.
Results: Seven of the 669 identiﬁed articles met the inclusion criteria, comprising 376 patients. Three trials
included 182 patients with ischaemic ulcers, two trials studied 64 patients with non-ischaemic ulcers, and two
trials comprising 130 patients did not specify ulcer type. Two trials were of good methodological quality. Pooling
of data was deemed inappropriate because of heterogeneity. Two RCTs in patients with ischaemic ulcers found
increased rates of complete healing at 1-year follow-up (number needed to treat (NNT) 1.8 (95% CI: 1.1 to 4.6)
and 4.1 (95% CI: 2.3 to 19)), but found no difference in amputation rates. A third trial in ischaemic ulcers found
signiﬁcantly lower major amputation rates in patients with HBOT (NNT 4.2, 95% CI: 2.4 to 17), but did not report
on wound healing. None of the RCTs in non-ischaemic ulcers reported differences in wound healing or
amputation rates. Two trials with unknown ulcer types reported beneﬁcial effects on amputation rates, although
the largest trial used a different deﬁnition for both outcomes. HBOT did not inﬂuence the need for additional
interventions.
Conclusion: Current evidence shows some evidence of the effectiveness of HBOT in improving the healing of
diabetic leg ulcers in patients with concomitant ischaemia. Larger trials of higher quality are needed before
implementation of HBOT in routine clinical practice in patients with diabetic foot ulcers can be justiﬁed.
 2014 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.
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Diabetic ulcers of the lower limb are a major healthcare
problem, and a major contributor to societal costs of dia-
betes. It has been estimated that 347 million people
worldwide have diabetes.1 In 1 year, one in 20 of these
patients will develop a foot ulcer, and over 10% of theserresponding author. R.M. Stoekenbroek, Dept. of Surgery, Academic
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//dx.doi.org/10.1016/j.ejvs.2014.03.005ulcers will result in an amputation.2 Indeed, some 50% of all
lower limb amputations are done in diabetic patients.3
Diabetic ulcers require complex multimodal treatment
including glycaemic control, extensive local wound care,
revascularization of ischaemic limbs (open and/or endo-
vascular) to improve peripheral circulation, treatment of
infections, and off-loading.4 Despite optimal care, complete
wound healing rates are reported to be as low as 60% after
1 year.5
Hyperbaric oxygen therapy (HBOT) has been suggested as
a valuable addition to conventional treatment for a variety
of indications, including delayed radiation injury, necrotizing
soft tissue infections and chronic wounds, particularly in
648 R.M. Stoekenbroek et al.patients with diabetes.6 HBOT for diabetic ulcers involves
intermittent administration of 100% oxygen, usually in daily
sessions of 90 minutes each, at pressures of 1.5e3.0 at-
mospheres absolute (ATA) in an airtight cabin.6,7 By
increasing the blood oxygen content, HBOT creates a
favourable gradient for the diffusion of oxygen into the
tissues. In hypoxic tissues, the enhanced oxygen supply has
multiple effects that may beneﬁt wound healing.7 By
increasing the expression of, among others, vascular endo-
thelial growth factor (VEGF) and ﬁbroblast growth factor
(FGF), HBOT may enhance angiogenesis and ﬁbroblast pro-
liferation. In addition, the resulting hyperoxia may cause
vasoconstriction, thereby decreasing tissue oedema. By
reducing the expression of pro-inﬂammatory cytokines,
HBOT reduces inﬂammation, while simultaneously
enhancing the bacterial killing activity of leukocytes.7e9
Although pooled estimates from randomized clinical trials
(RCTs) on HBOT in patients with diabetic ulcers in early
systematic reviews demonstrated increased rates of wound
healing and decreased major amputation rates when HBOT
was added to standard care,10e12 the reduction in ampu-
tation rates was not conﬁrmed in a recent large trial.13 The
subsequently updated Cochrane review reported increased
rates of ulcer healing in the short term (risk ratio (RR) 5.20,
95% CI: 1.25 to 21.66) but not in the long term (RR 9.53,
95% CI: 0.44 to 207.76), and no signiﬁcant difference in
major amputation rates (RR 0.36, 95% CI: 0.11 to 1.18).14
These results were conﬁrmed in the meta-analysis by
O’Reilly et al.15 Given that the ﬁndings of an additional RCT
were recently reported, a systematic review of all currently
available RCTs has been performed to assess whether HBOT,
when added to current best practice, can effectively
improve wound healing and prevent amputations in pa-
tients with diabetic foot ulcers. As it was hypothesized that
the presence of foot ischaemia may be a discriminating
factor for the effectiveness of HBOT, the evidence on the
effectiveness of HBOT in RCTs that included patients with
compromised versus normal peripheral circulation was
speciﬁcally compared.
METHODS
This review was done in accordance with the Preferred
Reporting Items for Systematic Reviews and Meta-Analyses
(PRISMA) statement, which has been updated to address
several conceptual and practical advances for performing a
systematic review of RCTs.16Search strategy
A clinical librarian assisted in formulating a search strategy
for the MEDLINE, Embase, and Cochrane databases to
identify RCTs on the effectiveness of HBOT in the treatment
of diabetic leg ulcers, published up to August 2013. Medical
Subject Headings (MeSH) terms were used, and accompa-
nying entry terms for the patient group and intervention.
The keywords ‘leg ulcers’, ‘diabetes’, and ‘hyperbaric
oxygenation’ were used, along with their synonyms. The full
search strategies are given in Appendix I. There were nolanguage restrictions. Reference lists of retrieved studies
were used to complete the search. In addition, www.
clinicaltrials.gov was searched for ongoing or terminated,
yet unpublished, trials. The aim was to contact the authors
of unpublished data (abstracts, conference proceedings, or
trials recorded in trial registers).
Trial selection
Titles and abstracts of potentially eligible articles were
independently screened by two of the authors (RS, MK) to
select potentially relevant articles. Studies were selected if
they met the following criteria: the patients had diabetes
and an ulcer of the lower extremity, and were randomly
allocated to standard care with or without HBOT, irre-
spective of the use of sham treatment, and the study re-
ported on amputation rates, wound healing, or additional
interventions. Any selection disagreements were resolved
by discussion. Agreement between the selecting authors
was good (Kappa value of 0.97). Subsequently, the full texts
of these potentially relevant articles were retrieved.
Data extraction
Two reviewers (RS, MK) independently extracted the data
using predeﬁned extraction forms. Data from multiple re-
ports of the same study were extracted on one data
collection form. Disagreement was handled by discussion.
Recorded study characteristics included publication type,
country and year, total number of patients included and
excluded, age, sex distribution, vascular status, single-centre
or multicentre design, duration of follow-up, time of
randomization, and details about the HBOT regimen used.
Recorded outcome measures included amputation rate,
which was reported separately for major (above ankle joint)
and minor (below ankle joint) amputations, proportion of
healed wounds, mean changes in ulcer size, surgical
debridement during follow-up, other additional in-
terventions, antibiotic therapy, and adverse events related
to HBOT. Authors of published trials were contacted when
additional information was required.
Quality assessment
The methodological quality of the included studies was
assessed by two reviewers (RS, MK) independently using a
modiﬁed version of the Cochrane checklist.17 The following
sources of bias were assessed: randomization; allocation
concealment; blinding of patients, clinicians, and assessors
to the received treatment; similarity of baseline character-
istics; completeness of follow-up of a sufﬁcient number of
patients; intention-to-treat analysis; and similarity of other
treatments beside the allocated treatment. Any discrep-
ancies were resolved by discussion.
Data analysis
Differences in dichotomous outcomes between the treat-
ment groups (e.g. rates of amputations and wound healing)
are expressed as risk differences (RD) and numbers needed
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 6 p. 647e655 June/2014 649to treat or harm (NNT or NNH) with 95% CI. Differences in
continuous outcomes (e.g. ulcer size) are reported as
weighted mean differences including 95% CI.
It was planned to perform a meta-analysis using a random
effects model a priori because of anticipated clinical and
statistical heterogeneity. If the I2 was above 70%, meta-
analysis was avoided and the reason for the study differ-
enceswas explored.18 To assess publication bias, an Egger test
and contour-enhanced funnel plots were performed.19 A
sensitivity analysis was planned to assess the effects of
including only studies of high methodological quality, and
subgroup analyses were considered to assess the effects of
different HBOT regimens and the presence of foot ischaemia.
RESULTS
669 potentially eligible articles were identiﬁed from the
databases. Fig. 1 presents the ﬂowchart of study inclusion
and reasons for exclusion. Finally, seven articles reporting
on seven RCTs fulﬁlled the inclusion criteria.13,20e25 These
articles were used for data extraction. Also identiﬁed was
the study protocol for a RCT in patients with diabetic foot
lesions persisting at least 3 weeks after optimal revascu-
larization on the www.oxynet.org website.26 This study was
started in 2002. The principal investigator involved was
contacted in this COST B14 project diabetic foot lesion
study. Although some 30 patients were included, the studyFigure 1. Flow diagram of article inclusion in the systematic review.was prematurely terminated, and a ﬁnal report has never
been published (personal communication).
Study characteristics
Study characteristics are listed in Table 1. Sample sizes
ranged from 18 to 100 patients, and follow-up varied be-
tween 2 weeks and more than 1 year. Most patients had
type II, as opposed to type I diabetes. The three largest trials
included only patients with ulcers classiﬁed as Wagner 2, 3,
and 4.13,22,23 Wounds had been present for at least 4 weeks,
and infected ulcers were not excluded. The trial by Doctor
et al. did not state how many of the 30 included patients
were allocated to each study arm.21
Study populations were heterogeneous, particularly as
to the wound characteristics and presence of ischaemia.
All included trials employed different deﬁnitions of
ischaemia. The study by Abidia et al. speciﬁcally investi-
gated ischaemic ulcers, deﬁned as an ankle-brachial pres-
sure index less than 0.8 or great toe-brachial pressure
index less than 0.7.20 The study population of the Faglia
trial primarily consisted of patients with compromised
peripheral circulation, as judged by the mean ankle blood
pressure and transcutaneous oxygen pressure (TcpO2),
although it is not apparent if patients with adequate
perfusion were excluded from participation.23 The Löndahl
trial included patients with adequate distal perfusion as
well as patients with non-reconstructable peripheral arte-
rial disease (PAD).13 Foot ischaemia, deﬁned as a toe blood
pressure of less than 60 mmHg, was present in 57% of
their study population. The median toe blood pressure was
52 mmHg. Kessler et al. and Ma et al. speciﬁcally included
non-ischaemic ulcers, as judged by palpable pulsations,
normal Doppler signals, and TcpO2.
24,25 Doctor et al. and
Duzgun et al. did not specify the presence of
ischaemia.21,22
Risk of bias
The results of the risk of bias assessment of the seven RCTs
are presented in Table 2. The overall methodological study
quality was mediocre. Most studies lacked proper reporting
of the treatment allocation procedure and two trials did not
report the blinding of assessors. Only two trials were of high
quality.13,20
Interventions
Two trials compared HBOT with 100% oxygen to hyperbaric
air, enabling blinding of patients and physicians with regard
to the treatment given.13,20 The other trials compared
HBOT plus standard care to standard care alone. HBOT
regimens were quite different among the trials, as the
number of HBOT sessions varied between 4 and 45. Table 3
summarizes the HBOT characteristics in each trial.
Study outcomes
Because the populations, interventions, and outcome
measures were widely heterogeneous, pooling of data was
Table 1. Baseline patient characteristics.
Doctor
199221
Faglia
199623
Abidia
200320
Kessler
200324
Duzgun
200822
Löndahl
201013
Ma
201325
N 30 70 18 28 100 94 36
Wagner grade
Grade 1 ? 6% ? 25%
Grade 2 ? 13% 94% ? 18% 26% 28%
Grade 3 ? 25% ? 37% 56% 47%
Grade 4 ? 62% None 45% 18%
Median wound
surface area
? ? Median
0.92 cm2
Mean 2.6
cm2
? Median 3.0
cm2
Mean 4.3
cm2
Wound duration ? ? >6 weeks >3 months >4 weeks >3 months >3 months
Median toe
blood pressure
? ? ? ? ? 52 mmHg ?
TcpO2 Mean: 45
mmHga
Dorsum of foot ? Mean 22.3
mmHg
Mean 45.4
mmHg
? Median 49
mmHgc
Mean 36.3
mmHg
Wound vicinity ? ? Mean 21.9
mmHgb
? ? Mean 37.1
mmHg
ABI ? Mean 0.65 Mean
GTPI 0.46
? ? ? ?
Ischaemic
ulcers included
? Yes Yes No ? Yes No
Diabetes type II
(%)
? ? 86% ? 67% 86.1%
Insulin therapy ? 63% 56% 93% 86% 90% 91.7%
TcpO2 ¼ Transcutaneous oxygen pressure; ABI ¼ Ankle/brachial pressure index; GTPI ¼ Great toe pressure index.
a Measurement location unknown.
b Only measured in the HBOT group.
c Values for patients who completed >36/40 sessions; obtained from different report of same study.
650 R.M. Stoekenbroek et al.deemed inappropriate. Therefore, the results of individual
studies are reported separately. For a detailed summary of
the main study outcomes see Table 4. In this table, the NNT
is given only for studies with a signiﬁcant difference be-
tween HBOT and control groups.
Wound healing and wound size reduction
In both of the two trials that included patients with
ischaemic ulcers and reported on wound healing, HBOT
resulted in improved rates of wound healing at the ﬁnal
follow-up visit compared with control patients, with an
NNT of 1.8 (95% CI: 1.1 to 4.6) and 4.1 (95% CI: 2.3 to 19),
respectively (Table 4).13,20 No increased rate of completeTable 2. Risk of bias assessment of the included trials.
Doctor
199221
Faglia
199623
Abid
2003
Adequate randomization method ? þ þ
Allocation concealment ? ? þ
Patient blinding   þ
Clinician blinding ? ? þ
Assessor blinding ? þ þ
Baseline similarity þ þ þ
Complete follow-up available ? þ þ
All patients accounted for ? þ þ
Intention-to-treat analysis ? þ þ
Similar co-interventions þ þ þwound healing has been demonstrated in either of the two
trials that excluded patients with ischaemic diabetic ulcers.
HBOT resulted in improved wound healing compared with
the control treatment in one of the two trials with un-
known leg perfusion (NNT 1.5 (95% CI: 1.3 to 1.9)).22
Three studies reported on reduction in wound size.20,24,25
In the study by Abidia et al. the median decrease in wound
surface area at 6 weeks was signiﬁcantly higher in the HBOT
than in the control group (100% vs. 52%, p ¼ .027).20
Kessler et al. found no difference in wound size reduction
after 4 weeks (62% vs. 55%).24 Ma et al. found an increase
in average reduction in ulcer size after 2 weeks in patients
treated with HBOT (42% vs. 18%, p < .05).25ia
20
Kessler
200324
Duzgun
200822
Löndahl
201013
Ma
201325
Total
(%)
þ þ þ þ 86
? ? þ ? 29
  þ  29
? ? þ ? 29
þ ? þ þ 71
þ  þ þ 86
þ ? þ þ 71
þ  þ þ 71
? ? þ ? 43
þ þ þ þ 100
Table 3. HBOT regimens and follow-up duration.
Doctor
199221
Faglia
199623
Abidia
200320
Kessler
200324
Duzgun
200822
Löndahl
201013
Ma
201325
HBOT sessions 4 38 30 20 30e45 40 20
Sham treatment No No Yes No No Yes No
Times daily ? 1, 5/7 days in
‘second phase’
1 2 2 and 1
(alternating)
1 2
HBOT duration (minutes) 45 90 90 90 90 85 90
HBOT pressure (ATA) 3 2.5, 2.2e2.4 in
‘second phase’
2.4 2.5 2e3 2.5 2.5
Duration of follow-up ? ? 1 year 4 weeks Mean: 92 weeks 1 year 2 weeks
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All seven trials reported major and minor amputation rates,
as listed in Table 4.
HBOT resulted in a signiﬁcant decrease in major ampu-
tations, with a NNT of 4.2 (95% CI: 2.4 to 17), in one of the
three studies that included patients with ischaemic ulcers.23
However, signiﬁcantly more minor amputations were per-
formed in patients who received additional HBOT in this
study. No effect on amputation rates was observed in the
other trials which included ischaemic ulcers.
In both trials that only included patients with adequate
peripheral blood circulation, no difference in amputation
rates was demonstrated.24,25
A reduction in amputation rates was reported in both
trials with patients with unknown vascular status. Doctor
et al., who reported the number of amputations but did not
specify the number of patients in each treatment group or
percentages, reported a statistically signiﬁcant reduction in
the number of major amputations (2 vs. 7, p < .05) in pa-
tients treated with HBOT, but not of minor amputations (4
vs. 2, p is non-signiﬁcant).21 In the trial by Duzgun et al.
HBOT resulted in a reduction in the number of major am-
putations, with an NNT of 2.9 (95% CI: 2.1 to 4.8).22 In
addition, in this study there was a reduction in the rates of
minor amputations in HBOT-treated patients. However, the
authors of this trial employed a different deﬁnition of major
and minor amputations from the other trials. Speciﬁcally,
amputations proximal to the metatarsophalangeal joint
(MTPJ) were deﬁned as major amputations. Therefore,
transmetatarsal amputations were classiﬁed as major am-
putations, whereas these amputations were classiﬁed as
minor amputations in the other trials. Unfortunately, the
authors did not respond to our request for additional in-
formation on the number of patients with an above-ankle
amputation.
None of the other studies found signiﬁcant differences in
minor amputation rates between HBOT and control
treatment.Additional interventions
The need for additional interventions was reported in four
trials. Two of the trials reported on percutaneous trans-
luminal angioplasty (PTA) or peripheral bypass surgery.13,23
In the Löndahl trial, which excluded patients who were
candidates for revascularization at baseline, a vascularreconstruction was performed during follow-up in 6/49
(12%) of patients in the HBOT group and in 4/45 (9%) of
patients in the control group.13 Revascularization rates were
also not signiﬁcantly different in the Faglia trial: 13/36
(36%) vs. 13/34 (38%), although patients who were candi-
dates for revascularization at inclusion were not excluded,
and no distinction was made between patients in whom
revascularization was performed prior to HBOT or only
during follow-up.23
Two trials reported on skin graft or ﬂap closure.21,22 In
the trial by Doctor et al., six skin grafts were used in the
HBOT group compared with two in the control group.21 In
the study by Duzgun et al., skin grafts or ﬂap closures were
only used in patients with Wagner grade IV ulcers, signiﬁ-
cantly more often in patients treated with HBOT: 4/25 (16%)
versus 0/20 (0%) (p < .05).22
Two trials reported on surgical debridement.22,23 Duzgun
et al. reported signiﬁcantly higher rates of surgical
debridement in the control group: 0/50 (0%) versus 9/50
(18%).22 In the study by Faglia et al., aggressive surgical
debridement was performed in all patients.23 Other studies
did not state the frequency of debridement or did not
distinguish between bedside debridement and debridement
performed in the operating room.Complications
Five trials reported on adverse events of HBOT.13,20,23e25
Two trials reported no adverse events.20,25 Three trials re-
ported 1/49 (2%), 1/36 (3%), and 2/15 (13%) cases of bar-
otraumatic otitis, respectively, which was a reason for
termination of treatment in at least one case.13,23,24 In the
Löndahl trial, myringotomy with tube placement due to
pain caused by the inability to equilibrate air pressure
through the Eustachian tube was performed in 2/49 (4%)
patients in the HBOT group, and in 2/45 (4%) in the hy-
perbaric air group.13 Hypoglycaemia was reported in 2/49
(4%) and 4/45 (9%) patients in the HBOT group and the
hyperbaric air group, respectively.13 Dizziness and wors-
ening of cataract were each described in 1/49 (2%)
patients.13
DISCUSSION
The available evidence on the effectiveness of HBOT for the
treatment of diabetic leg ulcers is not solid, both because of
clinical heterogeneity and methodological shortcomings of
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652 R.M. Stoekenbroek et al.the clinical trials. Within and between study clinical het-
erogeneity was substantial with regard to wound charac-
teristics and vascular status. Most studies were probably
underpowered, and only one study provided a sample size
calculation.23 Moreover, HBOT regimens varied widely
among the trials, as well as the deﬁnitions used for the
outcome measures major amputation and wound healing.
In addition, the duration of follow-up of some studies was
either not deﬁned or too short to yield meaningful, patient-
relevant outcomes. For these reasons it would be inap-
propriate to pool data in a meta-analysis.
By exploring the results of the individual studies some
evidence was found that HBOT improves wound healing in
ischaemic diabetic ulcers in the longer term, as opposed to
non-ischaemic diabetic ulcers. However, HBOT should not
be considered a substitute for optimal revascularization,27
and in all trials patients underwent revascularization if
indicated prior to HBOT. Given that optimal revasculariza-
tion is considered a prerequisite before using HBOT, it may
be noted that angiosome-directed revascularization has
increasingly been reported to achieve optimum perfusion of
ulcers.28,29 Although both of the trials that included pa-
tients with ischaemic ulcers with improved wound healing
were well-designed sham-controlled RCTs, the number of
patients was too small and the populations were too
diverse to draw deﬁnite conclusions.13,20 One of the trials
with unknown ulcer type reported a beneﬁcial effect on
wound healing, although this trial deﬁned wound healing as
healing without an intervention in the operating room.22
Remarkably, none of the 50 patients in the control group
reached this endpoint during the mean follow-up of 22
months. It should be noted that this trial was at an overall
unclear risk of bias, including blinding of caregivers and
outcome assessors, and that the outcome measure may be
particularly prone to performance bias.
It might be that the effectiveness of HBOT in patients
with ischaemic diabetic ulcers is underestimated. Two of the
trials used air at hyperbaric pressure in the control groups,
thus enabling the blinding of patients and clinicians.20,23
Although a study designed as such is ideal to prove the
concept of the effectiveness of HBOT, breathing air at hy-
perbaric pressure might also increase the blood oxygen
concentration, thereby possibly diluting a treatment effect,
as opposed to when standard wound care would have been
the comparator treatment.
We did not ﬁnd consistent evidence for HBOT preventing
major or minor amputations, either in patients with and
without concomitant foot ischaemia. Two out of the three
RCTs which included patients with foot ischaemia, which
were of acceptable methodological quality, reported no
signiﬁcant difference in major amputation rates.13,20 The
third trial on ischaemic ulcers did report signiﬁcantly
decreased major amputation rates, which was accompanied
by a signiﬁcant increase in minor amputations.23 The in-
crease in minor amputations may reﬂect limb salvage at the
expense of minor amputations. Two trials in patients with
unknown vascular status reported decreased major ampu-
tation rates, although these results cannot be compared
European Journal of Vascular and Endovascular Surgery Volume 47 Issue 6 p. 647e655 June/2014 653because of inconsistency in the deﬁnition of major versus
minor amputations.21,22
HBOT did not seem to decrease the need for revascu-
larization in patients in whom revascularization was not
indicated prior to HBOT, although this observation is
derived from a single RCT.13 Although revascularization
rates were reported in one additional trial, the report of this
trial does not distinguish between patients in whom
revascularization was performed at baseline, prior to HBOT,
or during follow-up, in patients who were not candidates for
revascularization at baseline.23
HBOT can generally be considered a safe treatment
modality, which is reﬂected by the low frequency of adverse
events in the trials included in this review. Reported side
effects include barotraumatic otitis, hypoglycaemia, and
worsening of cataract, as well as oxygen-induced seizures,
although the occurrence of such an event was not described
in the included RCTs.
It has been postulated that the addition of HBOT to
standard care in chronic diabetic foot ulcers is an effective
way of decreasing the overall costs of diabetic wounds.30
Yet, although insurance companies in the USA and Europe
reimburse HBOT for treatment of diabetic ulcers irre-
spective of their origin, the evidence for the effectiveness of
HBOT, at least in non-ischaemic diabetic ulcers, is limited
and therefore its cost-effectiveness remains to be
established.31,32
Recently, a retrospective cohort study of 6259 patients
with non-ischaemic diabetic foot ulcers which were
managed by a wound care company in the USA was pub-
lished.33 The results indicated that patients who were
treated with HBOT (n ¼ 793) had an increased risk of any
amputation (6.7% vs. 2.1%), a major amputation (3.3% vs.
1.3%), and a lower probability of wound healing (43.2% vs.
49.6%) after 16 weeks follow-up compared with patients
who did not have HBOT. These differences remained sta-
tistically signiﬁcant after adjustment for confounders. The
strength of this study is in the large number of patients
receiving HBOT who were included. Yet, several points of
criticism of the design and reporting of the study have been
expressed in a number of recent commentaries.34e38 First,
although the authors corrected for wound severity and
patient comorbidities through propensity scoring, many
known and unknown confounding factors may have intro-
duced selection bias, inherent to the retrospective design of
the study. Second, the majority of patients had Wagner
Grade II ulcers, whereas prospective trials have focussed
mainly on more severe ulcers. Third, follow-up was limited
to 16 weeks, and a longer follow-up may be required before
the maximal effect of HBOT can be demonstrated.13 Fourth,
the proportion of patients that completed all HBOT sessions
was unknown. Finally, although HBOT should only be
considered after optimal limb perfusion has been ach-
ieved,27 it is unclear if all patients underwent thorough
vascular examination to determine the indication for
revascularization, as the study report only states that
adequate perfusion was ‘determined by a physician’. In a
response, the authors of the study rightly state that theresults from RCTs often mirror the effectiveness of a study
treatment in an idealized, highly controlled setting, whereas
a cohort study may provide more reliable estimates of the
effectiveness of a study-treatment in a ‘real-world’
setting.39 This remark is important in light of the burden-
some nature of a full HBOT regimen, which may also limit
the feasibility and effectiveness of HBOT in practice. The
authors did not report information on the proportion of
patients who dropped out.
Liu et al. recently performed a meta-analysis of 13
controlled trials including RCTs, non-randomized controlled
trials and case-control studies, comprising a total of 624
patients with both ischaemic and non-ischaemic ulcers, and
reported signiﬁcantly increased healing rates (RR 2.33, 95%
CI: 1.51 to 3.60) and decreased major amputation rates (RR
0.29, 95% CI: 0.19 to 0.44).40 Results from observational
studies have also been summarized by O’Reilly et al.15 In
their pooled analysis of four comparative observational
studies comprising a total of 191 patients, additional HBOT
signiﬁcantly decreased the risk of major amputation (RR
0.39, 95% CI: 0.21 to 0.73). Although including observa-
tional studies increases sample size and decreases the risk
of publication bias, studies designed as such are obviously
biased, and the positive results could not be reproduced in
their meta-analysis of RCTs.15
A possible limitation of this systematic review is that
some RCTs in the ﬁeld might not have been located,
leading to publication bias. Yet, the search was extensive,
and it is believed that no important studies were missed.
Unfortunately, the unpublished data from the prematurely
stopped trial could not be included in this review.
Another possible limitation is that only RCTs were
included. Although such studies provide the highest level
of evidence, the total number of patients included in the
RCTs was low, which may limit the external validity of the
summarized data. Moreover, the strength of the evidence
provided by this review is limited because only two of the
included RCTs were considered to be of acceptable
quality.
In conclusion, considering the low quality of current
evidence, the high costs of HBOT, and the burdensome
nature of a full HBOT regimen, there is insufﬁcient evi-
dence to support the routine use of HBOT as an adjunct to
standard wound care in diabetic patients with foot ulcers.
Although there is some indication of a beneﬁcial effect on
wound healing, it is currently unknown which patients are
likely to beneﬁt from HBOT and which patients are not.
Before large-scale implementation of HBOT in routine
practice can be justiﬁed, its effectiveness needs to be
conﬁrmed in large RCTs of strong methodological quality
using uniform outcome measures to enable comparison of
outcomes. Moreover, future trials should identify the
subgroup of patients who are most likely to beneﬁt from
HBOT, establish the optimal HBOT regimen, and should be
adequately powered to identify a possible effect on
amputation rates. Given that previous RCTs have indicated
beneﬁcial effects of HBOT particularly in diabetic patients
with ischaemic leg ulcers, future research should
654 R.M. Stoekenbroek et al.speciﬁcally focus on these patients. Two multicentre trials
have recently started. The O’Reilly study (NCT00621608)
will include only patients without large vessel disease and
who are not candidates for revascularization, and the
DAMOCLES-trial (NTR3944) will speciﬁcally study patients
with ischaemic diabetic ulcers.41,42 The results of these
trials will contribute to evidence-based decision making on
the use of HBOT as an adjunctive therapy in patients with
a diabetic foot ulcer.
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APPENDIX 1. FULL SEARCH STRATEGY
MEDLINE (Pubmed)
January 1962 e August 2013. (Diabetic Foot[Mesh] OR Foot
Ulcer[Mesh] OR Leg Ulcer[Mesh] OR ((diabetes[tiab] OR
diabetic[tiab]) AND (foot[tiab] OR feet[tiab] OR ulcer*[tiab]
OR wound*[tiab])) OR (foot[tiab] AND ulcer*[tiab]) OR (feet
[tiab] AND ulcer*[tiab]) OR plantar ulcer*[tiab] OR leg ul-
cer*[tiab] OR ulcus cruris[tiab] OR crural ulcer*[tiab]) AND
(Hyperbaric Oxygenation[Mesh] OR (hyperbaric[tiab] AND
oxygen*[tiab]) OR HBO[tiab] OR HBOT[tiab] OR (oxygen*
[tiab] AND (high pressure[tiab] OR high tension[tiab])) OR
hyperbaric chamber*[tiab]) NOT case reportEmbase
January 1973 e August 2013. (‘leg ulcer’/OR ‘foot ulcer’/
OR ‘diabetic foot’/OR ‘diabetic feet’.ti,ab. OR (diabetes adj3
ulcer*).ti,ab. OR (diabetic adj3 ulcer*).ti,ab. OR (diabetic
adj3 wound*).ti,ab. OR (diabetes adj3 wound*).ti,ab. OR
(leg* adj3 ulcer*).ti,ab. OR (foot adj3 ulcer*).ti,ab. OR (ul-
cer* adj3 feet).ti,ab. OR (plantar* adj3 ulcer*).ti,ab. OR
‘ulcus cruris’.ti,ab. OR ‘crural ulcer’*.ti,ab. OR (diabetic adj3
foot).ti,ab. OR (diabetic adj3 feet).ti,ab.) AND (‘hyperbaric
oxygen’/exp OR ‘hyperbaric and oxygen*’.ti,ab. OR hbo.-
ti,ab. OR hbot.ti,ab. OR ‘hyperbaric chamber*’.ti,ab. OR
(oxygen* and (high pressure or high tension)).ti,ab.) NOT
case report/Cochrane library
To August 2013. #1 MeSH descriptor Diabetic Foot explode
all trees
#2 MeSH descriptor Foot Ulcer explode all trees
#3 MeSH descriptor Leg Ulcer explode all trees
#4 (diabet*):ti,ab,kw (foot):ti,ab,kw or (feet):ti,ab,kw or
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#8 (crural ulcer):ti,ab,kw
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(hyperbaric chamber*):ti,ab,kw
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